RBC Capital Starts Climb Bio (CLYM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts CLYM Hot Sheet
Price: $10.83 -1.55%
Rating Summary:
15 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
15 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
RBC Capital initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.
Shares of Climb Bio closed at $11.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- StoneX Starts SoFi Technologies (SOFI) at Buy
- S&P DJI and HKEX launch combined U.S. and Hong Kong tech index
- S&P Dow Jones Indices launches joint index with HKEX
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
